The Occupational Safety and Health Administration (OSHA) published a proposed carcinogenic standard in the Federal Register on 4 October 1977. In so proposing their "Cancer Policy" OSHA established itself among the government agencies (e.g. FDA, EPA) as "out in front in terms of stating explicitly what its cancer policies are."
OSHA contends that the policy must be based on four propositions: 1. the term "carcinogen" must be defined for purposes of regulatory activity;
2. as a policy matter, a toxic material confirmed as a carcinogen in mammalian test animals is to be treated as posing a carcinogenic risk to humans:
3. as a matter of general policy it must be considered that presently there is no means to determine a safe exposure level to a carcinogen; 4. when dealing with an identified "carcinogen." the permissible (worker) exposure level must be set as low as feasible.
According to the proposal OSHA would classify chemicals into one of four categories. Placement of a chemical into Category I would prompt immediate issuance of an "emergency temporary standard" (ETS). forcing reductions in worker exposures, medical surveillance as well as other "model" actions. Within 60 days of the classification rule making would begin in an effort to propose a permanent standard reducing exposure to the "lowest possible level, or prohibiting exposure entirely if a suitable substitute existed."
A chemical would be considered a Category I substance if it has been found to cause benign or malignant tumors in (a) humans, or (b) two mammalian test species, or (c) a single mammalian species, if those results have been replicated in the same species in another experiment, or (d) a single mammalian species, i f those result? are supported by short-term tests. This other "sufficient evidence" upon which the Secretary may base a Category I classification would include evidence that a substance 'generates non-statistically significant but extremely rare or unusual tumors such as brain tumorsthat might not otherwise, standing alone, meet the other criteria for Category I classification. This might also include evidence from a single, exceptionally well conducted test on one animal SDecies."
Category I1 classificatiorl would mean that a substance has been found positive in "an unreplicated WqXhV3nt in a single mammalian species" or that the Secretary again has found evidence "Sufficient" to justify placement into Category II. For Category II substances, an ETS would not be necessary but a permanent standard would have to be proposed no later than 60 days after the classification.
It is the intent of the proposal to promulgate a"mode1" ETS as well as model standards for Category 1 and II substances, respectively.
In rule making on permanent standards for Category I and II substances, issues to be left open for discussion would be limited so that the proceedings will not be bogged down by "traditionally" regulatory arguments such as the inapplicability of animal test data to humans, threshold levels, etc.
Category Ill classifications will be used where data re lacking but there is reason to believe that achemical may be a carcinogen.
In press release on this subject OSHA stated: "In particular, there appears to be general agreement on several major issues on which OSHA is relying in proposing these regulations."
OSHA continues: 1. "OSHA relies, in general, only upon resultsfound in testing of mammalian species, especially the rat and mouse, because they are directly relevant to man in carcinogenic testing."
2. "positive results in any mammalian species will, as a general rule, supersede negative findings in another species."
3. "positive animal data generally should supersede human data because of frequent defects in human studies."
4. "testing of substances at constant high exposure levels is required to overcome the statistical insensitivity of laboratory bioassays conducted with the limited number of animals that can be practically handled in laboratories."
5. "there can be no presumption that the organ affected in animal experiments would necessarily be affected in man."
6. "to place as much weight on an experiment in which only benign tumors are observed, as well both benign and malignant tumors are induced."
7. "to interpret the results of experiments showing increased incidence of tumors in treated animals as evidence of carcinogenicity, regardless of spontaneous cancer incidence.. . . ."
The above seven principles would define as a"carcinogen" any substance which once, in one biossay, in one strain of highly susceptible mouse, with a more than 50% incidenceof spontaneous tumors, produces an increased incidence of total benign plus malignant tumors, in all organs combined, at a maximally tolerated dose exposure.
Hearings on the proposal began in the spring of 1978 and are expected to continue into the summer of this year. Of particular interest to pathologists would probably be the testimony and rebuttal addressing the hypothesis of inevitable progression from benign to malignant, a prime focus of the testimonies of Drs. Stewart, Squire, Ruber, Dubin, and Butler. Donald Kennedy, US. Commissioner of Food and Drugs testified that the OSHA proposal is commendable and that FDA is incorporating similar systems into its regulations. S. John Byington, Chairman, U.S. Consumbr Product Safety Commission, testified in a similar vefh.
